180 Wealth Advisors LLC Has $404,000 Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

180 Wealth Advisors LLC lessened its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 10.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,823 shares of the company’s stock after selling 2,934 shares during the period. 180 Wealth Advisors LLC’s holdings in Elanco Animal Health were worth $404,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Jones Financial Companies Lllp acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $37,000. Tower Research Capital LLC TRC increased its holdings in shares of Elanco Animal Health by 169.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock worth $93,000 after buying an additional 3,906 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Elanco Animal Health in the 3rd quarter valued at $95,000. HBK Sorce Advisory LLC acquired a new position in Elanco Animal Health in the 4th quarter worth about $169,000. Finally, Allspring Global Investments Holdings LLC raised its position in Elanco Animal Health by 10.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock valued at $181,000 after purchasing an additional 1,127 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 5.3 %

Shares of NYSE ELAN traded up $0.75 during midday trading on Friday, reaching $15.02. The stock had a trading volume of 6,490,757 shares, compared to its average volume of 4,612,840. Elanco Animal Health Incorporated has a twelve month low of $8.52 and a twelve month high of $18.80. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29. The company’s 50 day moving average price is $16.40 and its 200 day moving average price is $15.66. The firm has a market cap of $7.42 billion, a price-to-earnings ratio of -5.67, a price-to-earnings-growth ratio of 1.74 and a beta of 1.45.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.93 EPS for the current year.

Analysts Set New Price Targets

ELAN has been the subject of several recent research reports. Barclays lowered their price objective on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday. Piper Sandler reaffirmed a “neutral” rating and set a $19.00 price target (up previously from $18.00) on shares of Elanco Animal Health in a research note on Monday, May 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Insider Buying and Selling

In other Elanco Animal Health news, Director William F. Doyle purchased 15,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were purchased at an average cost of $16.98 per share, for a total transaction of $254,700.00. Following the acquisition, the director now owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.57% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.